NCT04564703View on ClinicalTrials.gov

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

July 27, 2023

Study Completion Date

December 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Iberdomide

IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Trial Locations (4)

Unknown

CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes

Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens

Ospedale Generale Regionale-Divisione di Ematologia e Centro Trapianto Midollo Osseo, Bolzano

Vrije Universiteit Medical Center (VUMC), Amsterdam

All Listed Sponsors
collaborator

Healt Data Specialists - HeaDS (CRO)

UNKNOWN

collaborator

EMN Research Italy Impresa Sociale Srl

UNKNOWN

lead

Stichting European Myeloma Network

NETWORK